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Abstract
Purpose Over the last couple of years, we have witnessed the
availability of a wide variety of different therapeutic agents
and the identification of effective combinations of existing
ones that have transformed the way we approach and treat
pancreatic cancer. Proof of this are the recent validations that
combinations of conventional chemotherapy drugs, the
FOLFIRINOX regimen and gemcitabine plus nab-paclitaxel,
significantly improves clinical outcomes in patients with met-
astatic disease. However, deeper and more sophisticated un-
derstanding of the biology of this cancer as well as the ability
to develop better and perhaps more precise drugs predict that
the landscape may be changing even more.
Methodology and Results In this review, we will summarize
the most recent treatment advances including FOLFIRINOX,
gemcitabine plus nab-paclitaxel and discuss novel approaches
such as immune-mediated therapies, drugs that disrupt the
tumor-stromal compartment, PARP inhibitors for BRCA
pathway-deficient pancreatic cancer and new generations of
conventional chemotherapeutics, which are in early phases of
clinical development and have shown promising early results.
We will also discuss some examples of drugs that failed,
despite very good preliminary data, in order to appraise the
lessons learned from these negative clinical trials. Lastly, we
will comment on ongoing adjuvant and neoadjuvant trials.
Conclusion We hope that at least some of these will result in
positive trials and add to our armamentarium for treating this
challenging malignancy.
Keywords Pancreaticcancer .FOLFIRINOX .Nab-paclitaxel .
Gemcitabine . Erlotinib . Gastrointestinal cancer
Introduction
Pancreatic ductal adenocarcinoma (PDA) is undoubtedly one
of the most lethal cancers. Survival rates are still poor despite
the significant efforts over the years have been devoted to
studying this disease. Since the mid 1990s, gemcitabine
emerged as the main therapeutic armament to fight this dev-
astating disease; however, its real clinical benefit is a modest
1-month extension in the overall survival (OS; 5.6 vs.
4.4 months) when compared to 5-FU [1, 2]. Nevertheless,
these findings were encouraging and the next decade of re-
search involved numerous studies aimed at improving
gemcitabine efficacy and testing gemcitabine doublets,
resulting in minor improvements in OS.
Although pessimism has reigned for some time regarding
the likelihood of achieving substantial clinical improvement
in outcomes in PDA, the last few years have witnessed the
emergence of a variety of therapeutic strategies that have
already changed our daily practice. The first was the ver-
ification that a combination of chemotherapy agents
(FOLFIRINOX) could improve all the relevant clinical
outcomes in patients with metastatic disease [3]. The con-
fluence of a deeper and more sophisticated understanding
of pancreatic tumor biology plus the development of better
multi-agent combinations we suspect will foretell the avail-
ability of additional effective therapies in the near future.
The main objective of this review is to summarize recent
therapeutic advances that represent a substantial change in the
way we approach PDA in 2013. Pursuing this objective, we
will describe the new multi-agent combinations recently
FDA-approved, as well as drugs that are in the earlier phases
of development and that have shown promising results. Lastly,
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we will also discuss some examples of approaches that failed,
despite good preliminary data, to evaluate the lessons learned
from these negative clinical trials.
Recent Treatment Advances Already Available in Clinical
Practice
From a clinical perspective, PDA is divided into three main
categories: surgically resectable, locally advanced (LA), and
metastatic. We often say that surgery offers the only chance of
cure in PDA. While this statement is true, the actual cure rate
is low—about 3–5 % at 5 years [4]. Thus, advances in the
medical treatment are essential to obtain improvements in OS
even with early disease.
Three multi-agent chemotherapy regimens have resulted in
positive findings: FOLFIRINOX, gemcitabine + nab-
paclitaxel, and gemcitabine + erlotinib (Table 1).
FOLFIRINOX
FOLFIRINOX, a regimen composed of four drugs (Folinic
acid 400 mg/m2, 5-FU bolus 400 mg/m2 followed by 48 h
infusional 5-FU 2,400 mg/m2, Irinotecan 180 mg/m2, and
oxaliplatin 85 mg/m2) is currently considered a first-line treat-
ment option for metastatic PDA. Prior to the testing of this
multi-agent regimen, several trials explored the addition of a
second agent to gemcitabine in metastatic disease.
Gemcitabine was combined with platinum drugs (pooled
analysis, HR=0.85, P=0.01), with fluoropyrimidine (pooled
analysis, HR=0.90, P=0.03) as well as topoisomerase inhib-
itors (pooled analysis, HR=0.99, P=0.80) [2]. The median
OS ranged from 6 to 9 months, and the overall effect of adding
a second drug was a modest but detectable 10 % (CI: 3–15 %)
improvement in OS. This slight improvement in efficacy of
gemcitabine doublets was the rationale used by French inves-
tigators to study a multi-drug regimen that did not include
gemcitabine. They initially conducted a robust Phase II trial
demonstrating an impressive 26% response rate and a median
OS of 10.2 months [5]. Based on this and the fact that toxicity
although significant was manageable, investigators of the
PRODIGE Intergroup designed a randomized Phases II–III
clinical trial comparing FOLFIRINOX to single-agent
gemcitabine as first-line treatment for metastatic PDA [3]. A
number of 342 patients with histologically confirmed meta-
static disease and no significant comorbidities were enrolled.
The primary endpoint was OS; secondary endpoints were
PFS, tumor response (RECIST), safety, and quality of life.
The study was closed early when an interim analysis showed a
striking 4.3 months prolongation in median OS favoring
FOLFIRINOX (11.1 vs. 6.8 months; HR=0.57, P <0.001).
Median PFS was 6.4 vs. 3.3 months (P <0.001) and ORRwas
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increase in grades 3–4 toxicities mainly related to cytopenias,
neutropenic fever, diarrhea, vomiting, and peripheral neurop-
athy (all with P <0.01).
Since the publication of this pivotal clinical trial, many
single and multi-institutional studies have been reported
confirming the efficacy of this regimen. Twomain issues have
arisen regarding the general application of these findings. The
first pertains to the ability to utilize the entry criteria of the
Accord II trial for non-study metastatic PDA patients. To
address this, investigators from British Columbia performed
a retrospective review of 100 consecutive cases in their data-
base to determine the proportion of “real-world” patients that
would have met eligibility. They found that only 26 patients
would have been eligible, with the main reasons for exclusion
being older age (22 %), poor performance status (64 %), and
organ dysfunction (28 %) [6]. The second issue relates to
the tolerability of this regimen outside of the highly con-
trolled environment of a clinical trial. “Tolerability” of
FOLFIRINOX remains controversial with some reports
showing easily manageable side effects [7, 8], while others
demonstrate significant toxicity with 32 % hospitalization
[9] and treatment discontinuation in one third of the pa-
tients [10]. Conscious of these limitations, Mahaseth and
colleagues proposed a modified FOLFIRINOX in which
the 5-FU bolus was removed and growth factor prophylax-
is was used routinely. Authors reported significantly less
grade 3–4 toxicity but similar activity [11]. Additionally, in
a small retrospective analysis of 35 patients treated at the
Yale Cancer Center, 29 (85 %) who received dose-
attenuated FOLFIRINOX showed no significant reduction
in response rate [12]. These results are reassuring and have
enhanced the acceptability of this regimen among general
oncologists who frequently adjust drug doses based on the
individual patient's performance status. Of concern, how-
ever, is the possibility that personal physician modifica-
tions effect survival outcomes. This illustrates what is
common knowledge today that a minority of metastatic
patients are really candidates for FOLFIRINOX. We cer-
tainly need better biomarkers to assist us in determining
which patients really benefit from this regimen [13].
FOLFIRINOX has also been investigated in earlier stages
of disease. Kharofa and colleagues retrospectively evaluated
12 patients with unresectable PDA and who received neo-
adjuvant FOLFIRINOX followed by concurrent chemo-
radiation therapy with either gemcitabine or 5-FU. Seven
patients (58 %) had R0 resection and the median survival
was not reached after 13months of follow-up [14]. In a similar
retrospective analysis of 18 patients with unresectable and
borderline-resectable PDA, seven (39 %) were taken to the
OR after neoadjuvant FOLFIRINOX, five having R0, one R1
resections and one was not resectable [15]. Toxicity in this
population was significant with grades 3–4 toxicities including
neutropenia (22%), neutropenic fever (17%), thrombocytopenia
(11 %), fatigue (11 %), and diarrhea (11 %). In a second
retrospective single-institution experience with FOLFIRINOX
followed by chemo-radiation in LA PDA ORR was 27.3 % and
median PFS was 11.7 %. While 22 % (5 of 22) were able to
undergo R0 resections, the durability of these responses were
short with three developing distant metastases after 5months [9].
Lastly, investigators from the University of Pittsburgh reported
that 7 out of 25 patients with unresectable or borderline resect-
able PDA underwent surgical resection after receiving
FOLFIRINOX [16].
Nab-Paclitaxel
Nab-paclitaxel (Abraxane®) is an albumin-bound, 130-nM
particle, formulation of paclitaxel administered as a colloidal
suspension [17]. This drug was originally developed to over-
come the well-known anaphylactic reactions associated with
the conventional Cremophor EL formulation of paclitaxel.
However, this change in formulation presumably related to
the intra-tumoral drug delivery resulted in efficacy improve-
ment in PDA [18]. The molecular mechanism of this therapy
enhancement is not fully understood. It was originally thought
to be related to high expression of the protein SPARC, which
is known to bind albumin, by the tumoral stromal cells.
However, recent investigations suggested that an albumin
receptor (gp60) on endothelial cells could be involved in
transporting paclitaxel into the tumoral interstitial space [19].
Preclinical studies showed that the addition of nab-paclitaxel
to gemcitabine increases intratumoral gemcitabine levels due
to a marked decrease in the primary gemcitabine metabolizing
enzyme, cytidine deaminase, suggesting synergy between
these two drugs may contribute to clinical benefit in pancreatic
cancer [20].
The first proof of principle that nab-paclitaxel was effective
in metastatic PDA came from a Phase I/II trial in which nab-
paclitaxel plus gemcitabine was tested in 67 metastatic pa-
tients. After reaching a MTD of 125 mg/m2, 44 patients
completed the Phase II portion of the study showing a median
PFS of 7.9 months (95 % CI: 6–11 months), a median OS of
12.2 months (95 % CI: 9–18 months), and a 1-year survival of
48 % [21].
The open label, international, randomized Phase III trial
(MPACT study) was initially presented in 2013 at ASCO GI
and supports the use of the nab-paclitaxel/gemcitabine com-
bination in metastatic PDA. Investigators randomized 861
patients to either gemcitabine 1,000 mg/m2 alone for 7 weeks
followed by a rest week vs. nab-paclitaxel 125 mg/m2 plus
gemcitabine 1,000 mg/m2 for 3 weeks followed by a rest week
and treated until progression. The primary endpoint was OS
and secondary endpoints included PFS, ORR, safety, and
tolerability of this combination. The median OS was
8.5 months for the combination vs. 6.7 months for
gemcitabine alone (HR=0.72; P <0.001). Moreover, the time
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to treatment failure was significantly prolonged with the com-
bination from 3.5 to 5.1 months (HR=0.70; P <0.001). 1-year
survival was also improved (35 % vs. 22 %, P <0.001) [22].
Sub-analysis, presented at ASCO 2013, showed liver metas-
tases and poor PS (KPS<80) predicted the greatest advantage
of the combination. Based on this data, the FDA has approved
nab-paclitaxel plus gemcitabine as a first-line treatment option
for patients with metastatic PDA citing a high unmet need and
few effective treatments (announced in September 6, 2013).
As in the case of FOLFIRINOX, nab-paclitaxel is being tested
in earlier stages of disease [23, 24].
Erlotinib
Erlotinib plus gemcitabine is the only other drug combination
that has proven to be of some benefit in a randomized Phase
III clinical trial for patients with LA and metastatic PDA. In
2007, Canadian investigators presented the results of the NCI
PA.3 study in which 569 patients were randomly assigned to
gemcitabine 1,000 mg/m2 weekly for 7 weeks followed by a
week rest followed by 4-week cycles plus erlotinib 100–
150 mg or placebo [25]. Patients were treated until disease
progression or toxicity. The results showed a minimal im-
provement in median OS (6.2 vs. 5.9 months; HR=0.82,
P=0.038) and an absolute 6 % benefit in 1-year OS (23 %
vs. 17 %, P=0.023). The study also showed a statistically
significant improvement in DFS but no difference in ORR.
Patients receiving erlotinib experienced higher frequencies of
rash, diarrhea, infection, and stomatitis. There were six
protocol-related deaths, all in the arm containing erlotinib
attributed to interstitial pneumonitis (2), sepsis (2), neutrope-
nic sepsis (1), and CVA (1). A total of eight patients, seven in
the erlotinib group, developed an interstitial lung disease-like
syndrome. Since the publication of this clinical trial, there has
been significant controversy as to whether the short duration
of benefit is balanced by the risks. However, given the lack of
effective treatments, the combination did achieve FDA ap-
proval in November 2005.
Due to their greater potential for benefit, FOLFIRINOX
and gemcitabine plus nab-paclitaxel combination chemother-
apy are the preferable options for patients with better perfor-
mance status and organ function. Notwithstanding, and for
reasons not entirely clear, some patients respond unusually
well to erlotinib plus gemcitabine. A remarkable observation
reported in NCI PA.3 is the association between the develop-
ment of cutaneous rash and clinical outcome in erlotinib-
treated patients. Patients with grade≥2 skin rash had a 43 %
1-year survival and 10.5 months median OS in comparison
16 % and 5.3 months for those without rash, respectively
(P <0.001). Although technically a negative trial, with over-
all outcomes nearly identical to NCI PA.3, a similar correla-
tion regarding the predictive value of the skin rash was made
in an open label Phase II study of erlotinib 100 mg daily and
fixed-dose rate gemcitabine 1,000 mg/m2 [26]. Patients with
grade≥2 rash had a significantly higher chance of treatment
benefit (OS 42 vs. 15 weeks, P=0.03). The striking similarity
in survival between this trial and the NCI PA.3 also suggests
that the pharmacokinetic modulation of gemcitabine appears
to be of little clinical advantage [27]. In the Phase II RACHEL
trial, erlotinib was dose escalated from 150 to 250 mg/day
until at least grade 2 skin rash was obtained. Disappointingly,
dose escalation did not result in clinical benefit [28].
Novel Therapies in Early Phases of Clinical Development
There are now numerous follow-on trials testing
FOLFIRINOX and gemcitabine-nab-paclitaxel in earlier dis-
ease stages. Most notably, it is clear that both are effective in
LA PDA and the value of radiation in addition to multi-agent
chemotherapy is still to be determined. While we wait for
these trials to mature it is interesting to also speculate about a
number of novel therapies in the pipeline. Caution must
prevail when considering these therapies, as encouraging re-
sults in early phases of development do not necessarily trans-
late into clinically relevant outcomes, when tested in larger
populations or when compared with the standard of care.
Immunotherapy
We have recently witnessed a strong resurgence for immune
therapies in cancer treatments. The approval of sipuleucel-T
immunotherapy and ipilimumab to treat prostate and melano-
ma cancers are just two examples [29, 30]. PDA does not
seem to be the exception, although due to the aggressive
biology of this malignancy immune-based therapies have
generally been combined with chemotherapy.
A comprehensive review of the potential tumor-specific
antigens as well as the strategies used against PDA can be
found on other reviews and is beyond the scope of this
overview [31]. Briefly, potential methods of immune activa-
tion against pancreatic tumors include: (a) whole-cell vaccines
(e.g., genetically modified to over-express a particular epi-
tope); (b) peptide vaccines designed to boost CD 8+ cytotoxic
T-lymphocyte response; and (c) DNAvaccines in which mod-
ified DNA coding for a target antigen is inserted into a vector
which is directly taken up into tumoral cells.
Algenpantucel-L immunotherapy, a whole-cell allogenic
pancreatic cancer vaccine developed by NewLink Genetics
(Ames, IA, USA) is based on the concept of hyperacute
rejection that occurs with xenotransplantation. The vaccine
is composed of two irradiated human pancreatic cell lines that
have been genetically modified to over-express murineα(1,3)-
galactosyltransferase resulting in expression of α-galactosyl
(α-gal) epitopes on membrane glycoproteins and glycolipids.
Since these epitopes are not expressed by human cells an
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immediate hyperacute rejection response occurs similar to that
observed with transplant rejection. Vaccine exposure results in
antibody-dependent cell-mediated cytotoxicity with lysis of
cells containing the α-gal epitopes and the consequent devel-
opment of a strong T-cell mediated anti-tumor immunity. A
multi-institutional, open-label, Phase 2 trial was published
[32]. A number of 73 patients with resected PDA (R0 or R1)
received algenpantucel-L in addition to conventional
gemcitabine followed by 5-FU based chemo-radiation, as ad-
juvant treatment. Primary endpoint was 12-month DFS; sec-
ondary endpoints included OS and toxicity. 80 % patients had
positive lymph nodes. No significant side effects were reported
other than fatigue and local skin reactions. The median DFS
was 14 months and the 1-year DFS was 62 %. Median OS was
not reached but the 1-year OS was 86%. Higher vaccine doses
resulted in improved DFS (80 % vs. 51 %; P=0.02) and OS
(96 % vs. 79 %; P=0.053) at 12 months. A Phase III clinical
trial with similar design and a target of 722 subjects has just
completed enrollment.
Other Phase II clinical trials were reported with less en-
couraging results. Lutz et al. [33] designed a single-institution
adjuvant study of 60 patients with resected PDAwho received
an initial injection of an irradiated GM-CSF transfected whole
cell vaccine followed by 5-FU-based chemo-radiation therapy
and up to four additional immunizations. Median DFS and OS
were 17.3 and 24.8 months, respectively. Overall, the vaccine
was well tolerated. A randomized, multicenter, placebo-
controlled study with G17DT (Gastrimmune), an anti-
gastrin17 immunogen, showed a non-significant improve-
ment in OS compared to placebo in advanced disease [34].
Yanagimoto and colleagues [35] reported a median survival of
9 months with a 1-year survival rate of 38 % in 21 patients
with metastatic disease who received a personalized peptide
vaccine to HLA in combination with standard weekly
gemcitabine.
Stromal Disruption
Tumor stroma was once considered an inert bystander but is
now regarded as a key component of tumor biology. The
stroma of PDA is composed of an abundant extra-cellular
matrix that does not act simply as a mechanical support but
actively facilitates tumor development [36, 37]. The complex
interplay between cancer cells and the various components of
the tumor microenvironment has led to the testing of novel
therapies to interrupt these biological processes.
The first mechanism explored was the use of inhibitors of
the matrix metalloproteinases. Unfortunately, multiple studies
showed that this approach is quite ineffective [38]. A second
strategy involves the inhibition of cell-stroma interactions
fueled by soluble factors secreted from stromal cells and used
by tumors to enable the development of tumor vasculature or
tumor growth. Bevacizumab (Genentech/Roche) showed no
activity in multiple Phase I/II trials [39]. Sorafenib was also
ineffective in a Phase II study [40]. Dovitinib (an inhibitor of
FGFR-3) is being tested in combination with gemcitabine/
capecitabine in a Phase I trial. A randomized Phase II study
of tivantinib (small molecule inhibitor of c-Met) vs.
gemcitabine in treatment-naive patients with advanced PDA
was completed and results are pending. In a French Phase II
trial, 22 patients with LA or metastatic PDA received oral
masitinib (inhibitor of c-kit and PDGFR kinases) combined
with standard gemcitabine. The reported median TTP and OS
were 6.4 months and 7.1 months, respectively [41]. A Phase
III study recently updated in unresectable PDA using
gemcitabine plus masitinib vs. placebo showed no benefit in
OS (7.7 vs. 7.0 months); however, patients with a deleterious
genomic biomarker had a significant improvement in
OS (11 vs. 5 months, P <0.001) [42]. Rigosertib, a
phosphatidylinositol-3-kinase inhibitor, showed activity
in a Phase I trial [43] and is currently being tested in
a Phase II/III randomized clinical trial. Trabedersen, an
antisense molecule which is specifically designed to
target TGF-β2 mRNA, showed encouraging results in
Phase I/II and a Phase II is planned [44].
Three developmental pathways (WNT, notch, and the
hedgehog) have been implicated in induction of epithelial-
to-mesenchymal transformation as well as pancreatic cancer
progression and maintenance of cancer stem cells [45]. Many
new compounds targeting these pathways are being tested. A
recent Phase II clinical trial with hedgehog pathway inhibitor
saridegib (Infinity Pharmaceuticals) showed no benefit when
added to gemcitabine; but some activity was seen in a Phase Ib
trial with FOLFIRINOX [46]. Several Phase II trials of hedge-
hog pathway inhibitor vismodegib (Genentech/Curtis) and
Phase I trials of LDE225 (Novartis) in combination with
gemcitabine are ongoing. Notch inhibitors, RO4929097 and
MK0752, concluded Phase I studies and will move forward
into Phase II [47, 48]. We will have to wait until all these
studies are completed before any formal conclusion can be
made about this group of drugs.
PARP Inhibitors
Studies have demonstrated an increased risk of PDA among
relatives of patients with PDA 7.8 % compared to 0.6 % in
controls–even after adjusting for other factors [49]. In Ashke-
nazi Jews, a family history of PDA is a strong predictor for
BRCA2 mutation (OR=6.1) [50]. Familial pancreatic cancer
represents approximately 5 % of all newly diagnosed PDA
Genetic predisposition to PDA is polygenic; seen individuals
with mutations in Fanconi anemia pathway genes (BRCA2,
BRCA1, and PALB2), DNA mismatch repair genes (MSH2,
MSH6, MLH1, and PMS2), CDK2A/p16 (FAMMM syn-
drome), PRSS1 (hereditary pancreatitis), and LKB1/STK11
(Puetz-Jeghers) [51].
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BRCA1/2 harbors particular therapeutic interest because
homozygous mutant pancreatic cells are exquisitely sensitive
to DNA cross-linking agents such as mitomycin C and cis-
platin as well as PARP (Poly[ADP-ribose] polymerase) inhib-
itors [52]. There are several PARP-1 inhibitors in clinical
trials. At ASCO GI 2103, Pishvaian and colleagues presented
preliminary results of the Phase I portion of their trial com-
bining veleparib (ABT-888, Abbott Laboratories) with
FOLFOX in metastatic PDA. Of 22 patients treated on the
Phase I portion of the study, the two best responders were
patients with BRCA2 mutations; one had a PR with stable
disease after 17 months and the second had a CR with nor-
malization of CA 19–9 after 10 months [53]. The Phase II
portion of the study was modified to include patients with
known or suspected BRCA genetic mutations. Another Phase
II clinical trial of patients with confirmed BRCA1/2 mutation
treated with olaparib (AZD2281, AstraZeneca) monotherapy
was presented at ASCO 2013. A number of 23 patients were
included resulting in 1 CR, 4 PRs, and 8 SD for an ORR of
21.7, and 40.9 % 1-year survival [54]. Although final results
are not yet available, these results are encouraging.
Modified Conventional Chemotherapeutics
PEP02 (MM-398, Merrimack Pharmaceuticals) is a novel
nanoparticle liposomal formulation of irinotecan that has im-
proved pharmacokinetics and tumor biodistribution. In a re-
cent Phase II clinical trial of 40 patients with metastatic
gemcitabine-refractory PDA, PEP02 120 mg/m2 every
3 weeks showed a median PFS and OS of 9 and 21.6 weeks,
respectively. Grade 3/4 adverse events included cytopenias,
diarrhea and fatigue [55]. An international Phase III clinical
trial (NAPOLI 1; NCT01494506) of this product in combina-
tion with 5-FU is underway.
S-1(Teysuno®) is a fourth generation oral fluoropyrimidine
that contains tegafur, gimeracil, and oteracil potassium. In a
Japanese phase II, randomized trial (PC-01 Study), 116 pa-
tients with stages III–IV PDA were randomized to
gemcitabine plus S1 or placebo. Median (13.7 vs. 8.0 months)
and 1-year (29 % vs. 55.9 %) OS was better in the S-1 group
(P=0.035). However, treatment discontinuation due to toxic-
ity was seen in 27 % of the S-1 group [56]. S-1 is currently
approved for treatment of gastrointestinal malignancies in
Asia and Europe. A Phase III trial (JASPAC-01) of 385
patients comparing S-1 to gemcitabine for adjuvant therapy
of resected PDA. In this study powered for non-inferiority, S-1
was not only non-inferior (P <0.001) but also superior
(P <0.001) to gemcitabine. The authors concluded that
S-1 was better than gemcitabine and should be consid-
ered the new standard for resected PDA [57].
High-dose intravenous (IV) vitamin C (ascorbate) has been
shown to synergize with gemcitabine leading to enhanced
killing of tumor cells by a pro-oxidative mechanism. Two
Phase I studies have shown that combination of pharmaco-
logical doses of ascorbate with gemcitabine are safe in ad-
vanced pancreatic cancer [58, 59]. In the first, 8 of 14 patients
treated with gemcitabine and erlotinib in combination with
high-dose IV vitamin C had a reduction in the size of the
pancreatic primary. In the second, among nine patients PFS
was 26 weeks and OS was 12 months. Two Phase II trials are
currently ongoing testing the efficacy of high-dose IV ascor-
bate to enhance efficacy of gemcitabine-based chemotherapy.
Key Negative Trials
We will briefly discuss key Phases II–III clinical trials that
were negative, in spite of a strong biological rationale and/or
promising Phase II results. Table 2 serves as a summary.
Anti-VEGF
In 2010, the CALGB reported the results of a randomized
Phase III clinical trial in which 602 patients with stages III–IV
PDAwere randomized to receive either gemcitabine alone or
in combination with bevacizumab [39]. The results were
disappointing with no difference in median OS (5.8 vs.
5.9 months). In the preceding single-arm Phase II study, a
median 8.8 month OS and 21 % ORR was seen in 52 patients
with metastatic disease [60]. In reflection, the results of this
small, single-arm study were not significantly better than what
was previously published for gemcitabine alone. Fixed dose rate
gemcitabine plus bevacizumab followed by chemo-radiation
in LA potentially resectable disease fared no better [61].
Axitinib, an oral and selective inhibitor of VEGFs, current-
ly approved in the USA for advanced renal cell cancer, was
also tested in PDA. In a randomized placebo-controlled Phase
II study, 103 patients with unresectable or metastatic PDA
were treated with gemcitabine, with or without axitinib. The
ORR for gemcitabine plus axitinib was 7 % vs. 3 % for
gemcitabine alone, and themedian OSwas 6.9 vs. 5.6 months,
respectively [62]. Investigators interpreted this non-
statistically significant prolongation of 1.3 months as a signal
of activity and proceeded with a Phase III clinical trial enroll-
ing 632 patients [63]. In a pre-planned interim analysis done in
January 2009, an independent committee concluded the study
was futile and it was terminated. The reported median OS was
8.5 vs. 8.3 months (HR=1·014; 95 % CI: 0·786–1·309).
Cetuximab
At the same time that CALGB reported its negative study with
bevacizumab, the SWOG group released the results of a
randomized Phase III clinical trial of similar design using
cetuximab instead of bevacizumab. The median OS was 6.3
vs. 5.9 months for the experimental [64]. Again, the preceding
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study was a single-arm Phase II study of the combination of
cetuximab and gemcitabine that included only 41 patients.
Median OS of 7.1 months and a 12 % RR was felt to be
encouraging, but not significantly higher than gemcitabine
alone [65]. Negative results for this combination were also
observed in the adjuvant setting [66].
Insulin-Like Growth Factor Receptor (IGF-R) Blockade
Blockade of IGF-R1 is underpinned by strong pre-clinical
data [67, 68]. Ganitumab, Amgen's human monoclonal anti-
body that targets IGF-1R, was studied in combination with
gemcitabine in a Phase II trial of 42 patients with metastatic
disease. Median OS of 8.7 months and 1-year survival rates
were 39 % [69], slightly better than placebo. In August 2012,
following a preplanned interim analysis of the Phase III
GAMMA trial, Amgen stopped the study because the addition
of ganitumab to gemcitabine was unlikely to demonstrate
improvements in OS. Similarly, anti-IGF-1R monoclonal an-
tibody cixutumumab (ImClone) in combination with
gemcitabine/erlotinib did not improve PFS or OS inmetastatic
PDA [70]. A Phase II three-arm study of dalotuzumab (MK-
0646, Merck) in combination with gemcitabine with or with-
out erlotinib (NCT00769483) was recently completed.
Gemcitabine Elaidate (CO-1.01, CP-4126)
Gemcitabine elaidate is a lipophilic, unsaturated fatty acid
ester derivative of gemcitabine (Clovis) designed to allow
the drug to enter tumoral cells by passive diffusion and there-
fore independently of the human equilibrative nucleoside
transporter-1 (hENT1). The pivotal LEAP study, a random-
ized Phase II international clinical trial, required the measure-
ment of hENT in metastatic biopsies prior to randomization,
hoping to correlate hENT expression with gemcitabine bene-
fit. A number of 361 patients were enrolled rapidly, but
unfortunately, no difference in OS was found in either the
hENT1-low or in the overall intent-to-treat population. The
study also demonstrated that hENT1 status has no clinical
utility for determining gemcitabine sensitivity [71].
Future Directions in the Adjuvant and Neoadjuvant
Settings
At the current time, we do not know the benefit of multi-agent
chemotherapy in the adjuvant setting and therefore we still
rely on results of CONKO-1 and ESPAC-3 that demonstrated
a role for single-agent gemcitabine and 5-FU. The testing of
combination chemotherapy regimens in resectable and LA
disease is ongoing and hopefully will also lead to clinical
advances. Table 3 summarizes some of the most relevant
ongoing clinical trials.
The majority of the larger active trials are testing conven-
tional chemotherapy agent combinations. In the adjuvant set-
ting, the first trial that results are expected to be available is the
recently completed NewLink Genetics Phase III study that
compares standard of care gemcitabine with and without
HyperAcute-Pancreas immunotherapy (Algenpantucel-L)
followed by chemo-radiation. FOLFIRINIOX is being for-
mally tested in surgically resected disease by French investi-
gators (UNICANCER Group) in a Phase III clinical trial in
which subjects with R0 or R1 resections are randomized to a
modified version of FOLFIRINOX or standard gemcitabine.
The target number is 490 and the estimated completion date is
in 2018. The Phase III NCI-sponsored trial RTOG-0848 com-
pares erlotinib in combination with gemcitabine vs.
gemcitabine alone in the first randomization and the additional
benefit of chemoradiation in the second randomization. Esti-
mated enrollment is 950, with estimated completion of the
primary outcome measure (OS from 1st randomization)
targeted for 2020. Enrollment has been slow to this trial,
necessitating the addition of additional cooperative groups
and sites worldwide. An interesting Phase II ACOS trial
centered at MD Anderson also assesses the benefit of
gemcitabine and erlotinib in surgically-resectable disease. In
this study, two cycles of the 3 weeks on 1-week off combina-
tion is given prior to resection and reinitiated post-
pancreatiduodenectomy. Blood and tissue analysis is planned
for correlative studies. An alternative adjuvant approach is the
two-arm Phase III trial from Germany comparing gemcitabine
alone to gemcitabine plus cisplatin with regional hyperthermia
(HEAT, NCT01077427). The preceding Phase II trial demon-
strated a low toxicity rate and an OS of 16.9 months.
FOLFIRINOX has already been shown to be an effective
treatment option in LA PDA as demonstrated by several
single institution studies, with response rates as high as
50 % [14–16]. German investigators will assess the effective-
ness of chemotherapy and chemoradiation vs. chemotherapy
alone in LA unresectable pancreatic cancer in the four-arm
CONKO-7 trial. A total of 830 patients will first receive either
induction FOLFIRINOX or gemcitabine. Following comple-
tion of induction chemotherapy subjects will then receive
50.4 Gy radiation plus radiosensitizing gemcitabine OR con-
tinue with the same chemotherapy. The expected completion
date of this trial is 2018. A Phase II trial of similar design is
being conducted at MD Anderson (NCT01560949). Investi-
gators at Stanford University also plan to test FOLFIRINOX
in combination with chemoradiation; however, in this trial,
subjects will undergo treatment with modified FOLFIRINOX
plus or minus SBRT radiation with 5-FU as the
radiosensitizing agent. Secondary objectives include evalua-
tion of the utility of FDG- PET and biomarker identification.
The University of Florida has launched the Phase II GAIN-
1 trial in resectable and borderline-resectable pancreatic can-
cers testing gemcitabine + nab-paclitaxel as neoadjuvant
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therapy. Serological (CA 19.9), radiological, and pathological
response rate are the main outcomes. Lastly, European re-
searchers are currently testing another commonly used regi-
men (gemcitabine + oxaliplatin) in a Phase III clinical trial.
Patients assigned to the control arm will receive standard
surgical resection followed by adjuvant gemcitabine. Patients
on the investigational armwill receive 8 weeks of neoadjuvant
gemcitabine/oxaliplatin chemotherapy followed by surgery in
addition to gemcitabine adjuvantly. Preliminary results of this
trial will be available by the end of 2014.
Conclusions
We have summarized here the most recent treatment advances
in PDA, including the results of the FOLFIRINOX and nab-
paclitaxel plus gemcitabine Phase III trials. We discussed
novel approaches such as immune-mediated therapies, drugs
designed to disrupt the tumor-stromal compartment and to
take advantage of genetic defects in DNA repair as well as
new generations of conventional chemotherapeutics, all in
early stages of clinical development with promising results.
We hope that at least some of these agents will result in
positive trials and add to our armamentarium for treating this
challenging malignancy.
We are encouraged by recent leaps forward in the treatment
of PDA. Future research will focus on identifying molecularly
based clinical subtypes of pancreatic cancer and the further
development of criteria to assist in our clinical decision-
making. The long sought after goal of personalizing drug
choices based on pancreatic tumor and patient biology will
hopefully be possible. Can we define better biomarkers par-
ticularly for guidance in the neoadjuvant treatment of poten-
tially resectable disease? How will these recent advances,
primarily in the treatment of metastatic disease, help to im-
prove outcomes for surgically-amenable pancreatic cancer?
This of course is the treatment goal we are most asked by our
patients cure? With the availability of effective treatments for
metastatic PDA, we are now able to work toward this goal.
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